Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially osimertinib, are at the clinical frontier for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Regrettably, the rapidly developing drug resistance caused by EGFR mutations and the compensatory mechanism have largely limited their clinical efficacy. Given the synergistic effect between EGFR and other compensatory targets during tumorigenesis and tumor development, EGFR dual-target inhibitors are promising for their reduced risk of drug resistance, higher efficacy, lower dosage, and fewer adverse events than those of single-target inhibitors. Hence, we present the synergistic mechanism underlying the role of EGFR dual-target inhibitors against drug resistance, their structure-activity relationships, and their therapeutic potential. Most importantly, we emphasize the optimal target combinations and design strategies for EGFR dual-target inhibitors and provide some perspectives on new challenges and future directions in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors act on one or more targets with additive or synergistic effects, aiming to increase efficacy, prolong therapeutic effects, minimize side effects, and lower drug doses.68,69,525”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [69]
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Research works printed but not linked: 4
- Swarbrick M. E., 2012, Kinase Drug Discovery, 79
- Viloria-Petit A., 2001, Cancer Res., 61, 5090
- Marais R., 1996, Cancer Surv., 27, 101
- Matheson S. L., 2001, J. Pharmacology Experimental Therapeutics, 296, 832
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundSelf-citationRecent development of multi-target VEGFR-2 inhibitors for the cancer therapy
Liu, X., Zhao, H.-C., Hou, S.-J., Zhang, H., Cheng, L., Yuan, S., Zhang, L., Song, J., Zhang, S., & Chen, S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106425 · Cited by 142
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 125
Self-citationAhmad, S., & Raza, K. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10648-0 · Cited by 93
“Among the challenges medicinal chemists addressed was identifying polymorphism-related kinase inhibitors, one of the critical targets for EGFR tyrosine kinase inhibitors [15].”
Hu, M., Li, Y., Li, J., Zhou, H., Liu, C., Liu, Z., Gong, Y., Ying, B., & Xie, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114775 · Cited by 41
Metadata
- Authors
- Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., Ouyang, L., & Li, W.
- Affiliations
- Sichuan University (CN)
- Department of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China
- Corresponding author
- Wang, Chengdi
- Ouyang, Liang
- Li, Weimin
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-03-21
- Volume
- 65
- Issue
- 7
- Pages
- 5149-5183
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4221034213
- Cited by
- 88
- References
- 170
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 25 · 2023: 20 · 2022: 6
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
- National Natural Science Foundation of China (81874290, 81903502, 81922064, 82073318)
- National Clinical Research Center for Geriatrics, Sichuan University (Z20201004)
- Sichuan Science and Technology Program (2019YFS0003)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- epidermal growth factor receptor, dual inhibitors, EGFR-mutant non-small cell lung cancer, osimertinib, drug resistance, compensatory signaling, structure-activity relationship
- MeSH terms
- Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01714
- The paper
- Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., Ouyang, L., & Li, W. (2022). Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.